Default company panoramic image
Armune logo cmyk new

Armune BioScience, Inc.

Armune has developed, validated and is marketing a non-PSA prostate cancer diagnostic assay. It plans to develop an assay for lung and breast cancer.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Kalamazoo, MI, USA
  • Currency USD
  • Founded June 2008
  • Employees 8
  • Website

Company Summary

Armune BioScience is a medical diagnostics company formed to develop and commercialize unique technology for diagnostic and prognostic tests for prostate, lung and breast cancers. The technology utilizes autoantibodies created by the body’s own immune system to detect cancer at an early stage. When the immune system recognizes a cancer antigen, it creates an autoantibody to the antigen that is replicated by the immune system. Armune’s technology detects these autoantibodies in serum. A published study reported that lung cancer autoantibodies can be detected up to five years before clinical diagnosis of lung cancer , so Armune’s process of detecting these autoantibodies in serum offers a significant benefit and a competitive advantage.
Armune has developed and validated a new prostate cancer diagnostic assay that is being marketed under the Apifiny® trade name. The assay is marketed to urologists and primary care physicians as a Laboratory Developed Test (LDT) in accordance with the Clinical Laboratory Improvement Amendments (CLIA) guidelines.
The common practice when diagnosing prostate cancer is for the primary care physicians to request a PSA test in conjunction with an annual physical. Currently, the PSA test is the only prostate cancer screening test available, but it has several limitations. PSA is not a cancer-specific antigen and only indicates an abnormality of the prostate gland. As a result, an elevated PSA level may be prostate cancer, but it may also be the result of an enlarged prostate (BPH), an inflammation (prostatitis) or a urinary tract infection. Due to the limitations of PSA, there are unnecessary referrals from primary care to urology where additional tests/procedures are needed to determine if the man has prostate cancer. Under current American Urological Association guidelines, a PSA level greater than 2.5 ng/mL is suggestive of prostate cancer and the patient is normally referred to a urologist. The urologist will evaluate a number of factors when deciding whether the high PSA level indicates prostate cancer; the gold standard is to perform a TRUS (transrectal ultrasound) procedure and biopsy (normally 8 to 12 needles inserted into the prostate to obtain tissue). The prostate tissue is sent to a pathologist and 70 to 80% of the time, the results are negative for cancer. The obvious question is whether these biopsies are negative because the needles missed the tumor or whether the elevated PSA is due to other benign causes. The urologist’s primary concern is the false negative patient. It is estimated that 20 to 25% of men with a negative biopsy actually have prostate cancer. Consequently, a patient can remain in a highly anxious, “watchful waiting” period until his condition significantly changes or the urologist deems a follow-up biopsy is warranted.
Armune’s Apifiny assay may help to minimize the number of unnecessary referrals from primary care to urology and reduce the number of unnecessary prostate biopsies.


  • Default avatar
    Jeanne Ohrnberger, PhD
    Laboratory Director

    Jeanne has experience as a high-complexity CLIA laboratory director, and in developing in vitro diagnostics assays. During her career, Jeanne has become expert in molecular biology protocols, protein purification, and assay development covering a wide range of organisms, including fungi, plants, and humans. She also possesses familiarity with development scale up and manufacturing processes. Jeanne has a PhD in biochemistry from Wayne State.

  • Default avatar
    Jim Arthurs
    Chief Operations Officer

    Jim has extensive experience including FDA and CLIA regulated organizations, biotechnology, information technology, accounting consulting, electronics manufacturing, and nuclear medicine/physics. He has been involved in senior or executive management at five start-up companies including President of Biomedical Diagnostics, LLC. He holds a BS degree in Electrical Engineering from Pennsylvania State University.

  • Default avatar
    Eli Thomssen, MBA
    Chief Business Officer

    Eli is a founding partner of the Apjohn Group, which was organized to start new life science companies. Prior to that he worked more than 30 years at The Upjohn Company, which became Pharmacia & Upjohn. When Eli left Pharmacia & Upjohn, he was VP, Bus Development. Eli has been involved with several start-up companies, and has held numerous Board positions. Eli has a B.S. from the University of Nebraska and a MBA from Western Michigan University.

  • 5f31594b 38e9 4874 bf0c 077805a74a93
    President & CEO

    David has extensive commercialization experience as an executive in both the pharmaceutical and diagnostics market. Over a 15-year career with Merck & Co., David played key roles in sales, marketing, and commercial strategy. Most recently, David was the President and General Manager of Phadia US Inc., and was a key member of the Phadia leadership Team that successfully sold the business to Thermo Fisher Scientific for $3.5 billion USD in 2011.

  • Default avatar
    Susan Crookston

    Sue has 20 plus years of experience in various financial and human resource roles within the life sciences arena, including senior and management team experience at two start-up companies; Afmedica and CeeTox. Sue also worked for Apjohn Ventures as the Finance Director. Prior to working for start-ups, Sue held various financial leadership and analyst roles within The Upjohn Company, Pharmacia & Upjohn and Pfizer.


  • Default avatar
    Honigman Miller Schwartz and Cohn LLP and Wilson-Sonsini for IP
    Default avatar
    Jansen Valk Thompson & Reahm

Previous Investors

  • Default avatar
    Angels, Ann Arbor Spark, MEDC, and BRCC
    Default avatar
    Two grants